The aim of this study was to evaluate the cerebral amyloid distribution in patients with mild cognitive impairment (MCI), assessed by carbon-11-Pittsburgh compound B (11C-PIB) PET/CT, after 5 years of follow-up.
Ten amnestic MCI (A-MCI) and four nonamnestic (NA-MCI) patients were studied by 11C-PIB PET/CT and re-evaluated 5 years later by a new 11C-PIB PET/CT. PET/CT scans were acquired 60–90 min after the administration of 555 MBq 11C-PIB and analyzed visually, to obtain a score of the cerebral cortical 11C-PIB retention in the frontal, basal ganglia (BG), temporoparietal (TP), occipital, posterior cingulate, and cerebellum areas. Initial and 5-year follow-up 11C-PIB retentions were compared.
Initially, 9/10 A-MCI patients were 11C-PIB positive and one was 11C-PIB negative. All four NA-MCI patients were 11C-PIB negative. Of the 11C-PIB-positive A-MCI patients, seven progressed to Alzheimer’s disease dementia (AD-D), one to mixed dementia and one remained as A-MCI. The 11C-PIB-negative A-MCI patient remained as A-MCI. Of the four 11C-PIB-negative NA-MCI, one progressed to semantic dementia. All changes in 11C-PIB retention were of low intensity. The A-MCI patients who progressed to AD-D (n=7) showed an increase in 11C-PIB retention in the frontal (5/7), BG (3/7), TP (3/7), occipital (1/7), and posterior cingulate (1/7) regions. The A-MCI patient who progressed to mix dementia showed an increase in 11C-PIB retention in the frontal region. The 11C-PIB-positive A-MCI patient who remained as A-MCI showed an increase in 11C-PIB retention in the frontal, BG, and TP areas. The amyloid deposition in the anterior part of the brain (frontal, TP, and BG) increased more than that in the posterior part (occipital and precuneus) (7/9 vs. 2/9; P<0.05).
PIB retention increased predominantly in the frontal, BG, and TP areas. 11C-PIB-positive A-MCI patients mostly progressed to AD-D, showing similar topographic changes in their cerebral 11C-PIB pattern than the patient who remained as A-MCI.
Departments of aNuclear Medicine, Molecular Imaging Research Group (IDIVAL)
bNeurology, University Hospital ‘Marqués de Valdecilla’, University of Cantabria, Santander, Spain
Correspondence to Julio F. Jiménez-Bonilla, MD, Department of Nuclear Medicine, Molecular Imaging Research Group (IDIVAL), University Hospital ‘Marqués de Valdecilla’, 39008 Santander, Cantabria, Spain Tel: +34 942 315 155; fax: +34 942 315 167; e-mails: firstname.lastname@example.org, email@example.com
Received December 27, 2018
Received in revised form January 25, 2019
Accepted February 10, 2019